首页 > 最新文献

The Lancet Oncology最新文献

英文 中文
Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study Pembrolizumab联合lenvatinib作为胸膜间皮瘤(PEMMELA)患者的二线治疗:单臂2期研究的队列2
Pub Date : 2025-11-25 DOI: 10.1016/s1470-2045(25)00514-5
Li-Anne H Douma, Vincent van der Noort, Ferry Lalezari, Jeltje F de Vries, Kim Monkhorst, Illaa Smesseim, Paul Baas, Bodien Schilder, Marrit Vermeulen, Jacobus A Burgers, Cornedine J de Gooijer
{"title":"Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study","authors":"Li-Anne H Douma, Vincent van der Noort, Ferry Lalezari, Jeltje F de Vries, Kim Monkhorst, Illaa Smesseim, Paul Baas, Bodien Schilder, Marrit Vermeulen, Jacobus A Burgers, Cornedine J de Gooijer","doi":"10.1016/s1470-2045(25)00514-5","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00514-5","url":null,"abstract":"","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"30 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145592803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adjuvant capecitabine in early-stage triple-negative breast cancer? Yes, but for whom? 卡培他滨辅助治疗早期三阴性乳腺癌?是的,但对谁来说呢?
Pub Date : 2025-11-25 DOI: 10.1016/s1470-2045(25)00621-7
William M Sikov
{"title":"Adjuvant capecitabine in early-stage triple-negative breast cancer? Yes, but for whom?","authors":"William M Sikov","doi":"10.1016/s1470-2045(25)00621-7","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00621-7","url":null,"abstract":"","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"218 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145592810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Increased extent of neurosurgical resection in IDH-mutated glioma: issues for translation to standard practice idh突变胶质瘤的神经外科切除范围增加:转化为标准实践的问题
Pub Date : 2025-11-25 DOI: 10.1016/s1470-2045(25)00592-3
Michael Back
{"title":"Increased extent of neurosurgical resection in IDH-mutated glioma: issues for translation to standard practice","authors":"Michael Back","doi":"10.1016/s1470-2045(25)00592-3","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00592-3","url":null,"abstract":"","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"29 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145592816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SISAQOL-IMI consensus-based guidelines to design, analyse, interpret, and present patient-reported outcomes in cancer clinical trials SISAQOL-IMI基于共识的癌症临床试验设计、分析、解释和呈现患者报告结果的指南
Pub Date : 2025-11-25 DOI: 10.1016/s1470-2045(25)00520-0
Cecilie D Amdal, Ragnhild S Falk, Ahu Alanya, Michael Schlichting, Satrajit Roychoudhury, Vishal Bhatnagar, Lisa M Wintner, Antoine Regnault, Anders Ingelgård, Corneel Coens, Saskia le Cessie, Bernhard Holzner, Jane Chang, Martin Taphoorn, Paul Cislo, Johannes M Giesinger, Joseph C Cappelleri, Vivek Pawar, Silene ten Seldam, Elektra J Papadopoulos, Melanie J Calvert, Kenth L Joseph, Andrew Bottomley, Ingolf Griebsch, Juan I Arraras, Guro L Astrup, Ethan Basch, Andrej Belančić, Michael Brundage, Alicyn Campbell, Khadija Rerhou Rantell, Kim Cocks, Nathan Cherny, Sonya Eremenco, Montse Ferrer, Mallorie H Fiero, Christoph Gerlinger, Els Goetghebeur, Ulrich Grouven, Alexandra Lauer, Olalekan Lee Aiyegbusi, Abigirl Machingura, Junki Mizusawa, Geert Molenberghs, Morten Aa Petersen, Jaap C Reijneveld, Jolie Ringash, Gerhard Rumpold, Claudia Rutherford, Chantal Quinten, Kavita Sail, Maxime Sasseville, Willi Sauerbrei, Anja Schiel, Ashley W Smith, Claire Snyder, Galina Velikova, Xin S Wang, Kristin Bjordal, Madeline Pe, Solomon Alexi, Imad Al-naesan, Jennifer Black, Florien Boele, Kris Bogaerts, Sarah Böhme, Ting-Yu Chen, Francesca Chiavaro, Vincent Claus, Charlie Cleeland, Cheryl Coon, Samantha Cruz Rivera, Gracia Dekanic Arbanas, Gregoire Desplanques, Nnadozie Emechebe, Kristina Fitzgerald, Olatz Garin, Miaomiao Ge, Alexandra Gilbert, Mogens Groenvold, Franziska Gross, Erica Horodniceanu, Laura Lee Johnson, Katie Joyner, Rajesh Kamalakar, Madeleine King, Paul Kluetz, Karin Kuljanic, Nicola Latino, Limin Liu, Morine Maguri, Francesca Martinelli, Flora Mazerolle, Sandra Mitchell, Kate Morgan, Jammbe Musoro, David Ness, Irene Nsiah, Sjoukje Oosting, Rosemary Peacock
{"title":"SISAQOL-IMI consensus-based guidelines to design, analyse, interpret, and present patient-reported outcomes in cancer clinical trials","authors":"Cecilie D Amdal, Ragnhild S Falk, Ahu Alanya, Michael Schlichting, Satrajit Roychoudhury, Vishal Bhatnagar, Lisa M Wintner, Antoine Regnault, Anders Ingelgård, Corneel Coens, Saskia le Cessie, Bernhard Holzner, Jane Chang, Martin Taphoorn, Paul Cislo, Johannes M Giesinger, Joseph C Cappelleri, Vivek Pawar, Silene ten Seldam, Elektra J Papadopoulos, Melanie J Calvert, Kenth L Joseph, Andrew Bottomley, Ingolf Griebsch, Juan I Arraras, Guro L Astrup, Ethan Basch, Andrej Belančić, Michael Brundage, Alicyn Campbell, Khadija Rerhou Rantell, Kim Cocks, Nathan Cherny, Sonya Eremenco, Montse Ferrer, Mallorie H Fiero, Christoph Gerlinger, Els Goetghebeur, Ulrich Grouven, Alexandra Lauer, Olalekan Lee Aiyegbusi, Abigirl Machingura, Junki Mizusawa, Geert Molenberghs, Morten Aa Petersen, Jaap C Reijneveld, Jolie Ringash, Gerhard Rumpold, Claudia Rutherford, Chantal Quinten, Kavita Sail, Maxime Sasseville, Willi Sauerbrei, Anja Schiel, Ashley W Smith, Claire Snyder, Galina Velikova, Xin S Wang, Kristin Bjordal, Madeline Pe, Solomon Alexi, Imad Al-naesan, Jennifer Black, Florien Boele, Kris Bogaerts, Sarah Böhme, Ting-Yu Chen, Francesca Chiavaro, Vincent Claus, Charlie Cleeland, Cheryl Coon, Samantha Cruz Rivera, Gracia Dekanic Arbanas, Gregoire Desplanques, Nnadozie Emechebe, Kristina Fitzgerald, Olatz Garin, Miaomiao Ge, Alexandra Gilbert, Mogens Groenvold, Franziska Gross, Erica Horodniceanu, Laura Lee Johnson, Katie Joyner, Rajesh Kamalakar, Madeleine King, Paul Kluetz, Karin Kuljanic, Nicola Latino, Limin Liu, Morine Maguri, Francesca Martinelli, Flora Mazerolle, Sandra Mitchell, Kate Morgan, Jammbe Musoro, David Ness, Irene Nsiah, Sjoukje Oosting, Rosemary Peacock","doi":"10.1016/s1470-2045(25)00520-0","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00520-0","url":null,"abstract":"","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145592817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study Camrelizumab + rivoeranib vs sorafenib作为不可切除肝细胞癌的一线治疗(CARES-310):一项随机、开放标签、国际、3期研究的最终分析
Pub Date : 2025-11-25 DOI: 10.1016/s1470-2045(25)00543-1
Shukui Qin, Shanzhi Gu, Stephen L Chan, Yuxian Bai, Zhenggang Ren, Xiaoyan Lin, Zhendong Chen, Weidong Jia, Yongdong Jin, Yabing Guo, Xiaohua Hu, Zhiqiang Meng, Jun Liang, Jianping Xiong, Hong Ren, Fang Yang, Wei Li, Yajin Chen, Yong Zeng, Li Xu, Xianglin Yuan, Da Li, Alexander Sultanbaev, Monika Pazgan-Simon, Margaryta Pisetska, Davide Melisi, Dmitriy Ponomarenko, Jinghua Du, Wei Shi, Ann-Lii Cheng, Ahmed Kaseb, Arndt Vogel
{"title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study","authors":"Shukui Qin, Shanzhi Gu, Stephen L Chan, Yuxian Bai, Zhenggang Ren, Xiaoyan Lin, Zhendong Chen, Weidong Jia, Yongdong Jin, Yabing Guo, Xiaohua Hu, Zhiqiang Meng, Jun Liang, Jianping Xiong, Hong Ren, Fang Yang, Wei Li, Yajin Chen, Yong Zeng, Li Xu, Xianglin Yuan, Da Li, Alexander Sultanbaev, Monika Pazgan-Simon, Margaryta Pisetska, Davide Melisi, Dmitriy Ponomarenko, Jinghua Du, Wei Shi, Ann-Lii Cheng, Ahmed Kaseb, Arndt Vogel","doi":"10.1016/s1470-2045(25)00543-1","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00543-1","url":null,"abstract":"","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"163 2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145593399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Misclassification of p16-positive, HPV-negative patients biases de-escalation trials – Authors' reply p16阳性、hpv阴性患者的错误分类会影响降级试验——作者的回复
Pub Date : 2025-11-25 DOI: 10.1016/s1470-2045(25)00655-2
David M Routman, James S Lewis, Daniel J Ma
{"title":"Misclassification of p16-positive, HPV-negative patients biases de-escalation trials – Authors' reply","authors":"David M Routman, James S Lewis, Daniel J Ma","doi":"10.1016/s1470-2045(25)00655-2","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00655-2","url":null,"abstract":"","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"187 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145592800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial 节律卡培他滨作为早期三阴性乳腺癌的延长辅助化疗(syscc -001):一项随机3期试验的最新10年结局和事后探索性生物标志物分析
Pub Date : 2025-11-25 DOI: 10.1016/s1470-2045(25)00545-5
Jing Yuan, Xi-Wen Bi, Xin Hua, Heng Huang, Li Cai, Li Zhao, Qian-Jun Chen, Xin-Xin Chen, Xu-Lin Wang, Ying Lin, An-Qing Zhang, Yong-Yi Zhong, Fei Xu, Jia-Jia Huang, Xin An, Yan-Xia Shi, Xi Wang, Shu-Sen Wang, Cong Xue, Zhong-Yu Yuan
{"title":"Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial","authors":"Jing Yuan, Xi-Wen Bi, Xin Hua, Heng Huang, Li Cai, Li Zhao, Qian-Jun Chen, Xin-Xin Chen, Xu-Lin Wang, Ying Lin, An-Qing Zhang, Yong-Yi Zhong, Fei Xu, Jia-Jia Huang, Xin An, Yan-Xia Shi, Xi Wang, Shu-Sen Wang, Cong Xue, Zhong-Yu Yuan","doi":"10.1016/s1470-2045(25)00545-5","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00545-5","url":null,"abstract":"","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145592814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to Lancet Oncol 2025; 26: 1443–53 《柳叶刀-肿瘤》2025年修正;26日:1443 - 53年
Pub Date : 2025-11-25 DOI: 10.1016/s1470-2045(25)00668-0
{"title":"Correction to Lancet Oncol 2025; 26: 1443–53","authors":"","doi":"10.1016/s1470-2045(25)00668-0","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00668-0","url":null,"abstract":"","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145592825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to Lancet Oncol 2024; 25: 1038–52 《柳叶刀肿瘤学杂志》2024年更正;25: 1038 - 52
Pub Date : 2025-11-25 DOI: 10.1016/s1470-2045(25)00522-4
{"title":"Correction to Lancet Oncol 2024; 25: 1038–52","authors":"","doi":"10.1016/s1470-2045(25)00522-4","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00522-4","url":null,"abstract":"","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145592804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SunRISe-4 perioperative safety and TURBT stratification – Authors' reply SunRISe-4围手术期安全性与TURBT分层——作者回复
Pub Date : 2025-11-25 DOI: 10.1016/s1470-2045(25)00671-0
Andrea Necchi, Hind Stitou, Sumeet Bhanvadia, Sarah P Psutka
{"title":"SunRISe-4 perioperative safety and TURBT stratification – Authors' reply","authors":"Andrea Necchi, Hind Stitou, Sumeet Bhanvadia, Sarah P Psutka","doi":"10.1016/s1470-2045(25)00671-0","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00671-0","url":null,"abstract":"","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"114 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145592807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
The Lancet Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1